163 related articles for article (PubMed ID: 16761934)
1. Immunomodulatory and antitumor effects of interleukin-21 in patients with renal cell carcinoma.
Curti BD
Expert Rev Anticancer Ther; 2006 Jun; 6(6):905-9. PubMed ID: 16761934
[TBL] [Abstract][Full Text] [Related]
2. Interleukin 21 enhances antibody-mediated tumor rejection.
Smyth MJ; Teng MW; Sharkey J; Westwood JA; Haynes NM; Yagita H; Takeda K; Sivakumar PV; Kershaw MH
Cancer Res; 2008 Apr; 68(8):3019-25. PubMed ID: 18413772
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-21 activates cytotoxic T lymphocytes and natural killer cells to generate antitumor response in mouse renal cell carcinoma.
Kumano M; Hara I; Furukawa J; Oniki S; Nagai H; Miyake H; Fujisawa M
J Urol; 2007 Oct; 178(4 Pt 1):1504-9. PubMed ID: 17707061
[TBL] [Abstract][Full Text] [Related]
4. Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma.
Kato Y; Yoshimura K; Shin T; Verheul H; Hammers H; Sanni TB; Salumbides BC; Van Erp K; Schulick R; Pili R
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4538-46. PubMed ID: 17671140
[TBL] [Abstract][Full Text] [Related]
5. In vivo antitumor activity of interleukin 21 mediated by natural killer cells.
Wang G; Tschoi M; Spolski R; Lou Y; Ozaki K; Feng C; Kim G; Leonard WJ; Hwu P
Cancer Res; 2003 Dec; 63(24):9016-22. PubMed ID: 14695220
[TBL] [Abstract][Full Text] [Related]
6. Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer.
van der Vliet HJ; Koon HB; Yue SC; Uzunparmak B; Seery V; Gavin MA; Rudensky AY; Atkins MB; Balk SP; Exley MA
Clin Cancer Res; 2007 Apr; 13(7):2100-8. PubMed ID: 17404092
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-21: updated review of Phase I and II clinical trials in metastatic renal cell carcinoma, metastatic melanoma and relapsed/refractory indolent non-Hodgkin's lymphoma.
Hashmi MH; Van Veldhuizen PJ
Expert Opin Biol Ther; 2010 May; 10(5):807-17. PubMed ID: 20384523
[TBL] [Abstract][Full Text] [Related]
8. Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy.
Varker KA; Kondadasula SV; Go MR; Lesinski GB; Ghosh-Berkebile R; Lehman A; Monk JP; Olencki T; Kendra K; Carson WE
Clin Cancer Res; 2006 Oct; 12(19):5850-8. PubMed ID: 17020993
[TBL] [Abstract][Full Text] [Related]
9. Membrane-bound interleukin (IL)-15 on renal tumor cells rescues natural killer cells from IL-2 starvation-induced apoptosis.
Wittnebel S; Da Rocha S; Giron-Michel J; Jalil A; Opolon P; Escudier B; Validire P; Khawam K; Chouaib S; Azzarone B; Caignard A
Cancer Res; 2007 Jun; 67(12):5594-9. PubMed ID: 17575122
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-21 and the IL-21 receptor: novel effectors of NK and T cell responses.
Parrish-Novak J; Foster DC; Holly RD; Clegg CH
J Leukoc Biol; 2002 Nov; 72(5):856-63. PubMed ID: 12429707
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-21 signaling: functions in cancer and autoimmunity.
Davis ID; Skak K; Smyth MJ; Kristjansen PE; Miller DM; Sivakumar PV
Clin Cancer Res; 2007 Dec; 13(23):6926-32. PubMed ID: 18056166
[TBL] [Abstract][Full Text] [Related]
12. Effects of interleukin-2 treatment on CD1d-restricted natural killer T cells.
Sandberg JK; Moll M
Clin Cancer Res; 2007 Jul; 13(14):4311; author reply 4311-2. PubMed ID: 17634562
[No Abstract] [Full Text] [Related]
13. Antitumor efficacy of recombinant human interleukin-2 combined with sorafenib against mouse renal cell carcinoma.
Iguchi M; Matsumoto M; Hojo K; Wada T; Matsuo Y; Arimura A; Abe K
Jpn J Clin Oncol; 2009 May; 39(5):303-9. PubMed ID: 19336449
[TBL] [Abstract][Full Text] [Related]
14. Safety and clinical effect of subcutaneous human interleukin-21 in patients with metastatic melanoma or renal cell carcinoma: a phase I trial.
Schmidt H; Brown J; Mouritzen U; Selby P; Fode K; Svane IM; Cook GP; Mollerup DH; Geertsen PF
Clin Cancer Res; 2010 Nov; 16(21):5312-9. PubMed ID: 20959407
[TBL] [Abstract][Full Text] [Related]
15. Lymphocyte therapy of renal cell carcinoma.
Dillman RO
Expert Rev Anticancer Ther; 2005 Dec; 5(6):1041-51. PubMed ID: 16336095
[TBL] [Abstract][Full Text] [Related]
16. Peripheral gammadelta T-lymphocytes as an innovative tool in immunotherapy for metastatic renal cell carcinoma.
Viey E; Laplace C; Escudier B
Expert Rev Anticancer Ther; 2005 Dec; 5(6):973-86. PubMed ID: 16336088
[TBL] [Abstract][Full Text] [Related]
17. [Clinical trial of IL-12 for cancer patients].
Ohe Y; Kasai T; Heike Y; Saijo N
Gan To Kagaku Ryoho; 1998 Jan; 25(2):177-84. PubMed ID: 9474926
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-2 based immunotherapy in patients with metastatic renal cell carcinoma.
Donskov F
Dan Med Bull; 2007 Nov; 54(4):249-65. PubMed ID: 18208677
[TBL] [Abstract][Full Text] [Related]
19. Maintenance biotherapy with interleukin-2 and interferon for metastatic renal cell cancer.
Porta C
Expert Rev Anticancer Ther; 2006 Jan; 6(1):141-52. PubMed ID: 16375651
[TBL] [Abstract][Full Text] [Related]
20. Complex perioperative immuno-dysfunction in patients with renal cell carcinoma.
Böhm M; Ittenson A; Philipp C; Röhl FW; Ansorge S; Allhoff EP
J Urol; 2001 Sep; 166(3):831-6. PubMed ID: 11490228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]